Rentschler Biopharma announces strategic realignment of its global business operations

LAUPHEIM, Germany, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations as part of a long-term strategic shift. As part of this realignment, Rentschler Biopharma will withdraw from the field of cell and gene therapy, ceasing operations at its Stevenage, UK site, and increase its focus on biologics1. This decision is embedded in the company’ ...